肺癌免疫治疗超进展的研究进展

摘要
图/表
参考文献(32)
相关文章 (15)

全文: PDF (579 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要近年来，由于对肿瘤微环境的深入认识，肿瘤免疫治疗的临床研究突飞猛进，免疫治疗成为肿瘤治疗领域的热点。由于免疫检查点抑制剂在非小细胞肺癌患者中显示明显生存优势，免疫治疗越来越广泛地应用于肺癌患者的治疗中，使用免疫治疗后出现的特殊反应现象也逐渐引起人们的重视。部分肺癌患者在接受免疫治疗后发生“假性进展”和“超进展”现象，但目前关于如何准确定义和区分两者存在争议，正确评估这种独特的肿瘤反应具有挑战性。本文对免疫治疗超进展现象的识别、评估标准、高危人群及相关预测因子的研究进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张雯宋启斌

关键词 ：肺癌, 免疫治疗, 超进展, 免疫检查点抑制剂

Abstract：In recent years, due to futher understanding of tumor microenvironment, the clinical research of tumor immunotherapy has made great progress, and immunotherapy has become a hot spot in the field of tumor therapy. Since the significant survival advantage of immunocheckpoint inhibitors in non small cell lung cancer patients, immunotherapy is more and more widely used in lung cancer patients, and the special reaction phenomenon after immunotherapy has gradually attracted people′s attention. There are reports showing that the phenomenon of pseudoprogressio and hyperprogressive occurs in some lung cancer patients after immunotherapy. However, there are currently controversies about how to accurately define and distinguish them, and it is challenging to correctly assess this unique tumor response. This article reviews the research on the definition, evaluation criteria, high-risk groups and related predictors of hyperprogression after immunotherapy.

Key words： Lung cancer Immunotherapy Hyperprogression Immune checkpoint inibitors

基金资助:国家自然科学基金资助项目（81670123）。

通讯作者: 宋启斌（1962.8-），男，博士，主任医师，博士生导师；研究方向：肿瘤的基础与临床研究。

作者简介: 张雯（1992.3-），女，武汉大学第一临床医学院2017级肿瘤学专业在读硕士研究生；研究方向：肿瘤的基础与临床研究。

引用本文:

张雯宋启斌. 肺癌免疫治疗超进展的研究进展[J]. 中国医药导报, 2020, 17(31): 58-61.
ZHANG Wen SONG Qibin. Research progress on hyperprogression of immunotherapy for lung cancer. 中国医药导报, 2020, 17(31): 58-61.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I31/58

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy [J]. Science，2013，342（6165）：1432-1433.
[3] Hamid O，Robert C，Daud A，et al. Safety and tumor responses with lambrolizumab（anti PD-1）in melanoma [J]. N Engl J Med，2013，369（2）：134-144.
[4] Ansell SM，Lesokhin AM，Borrello I，et al. PD-1 Blockade with Nivolumab in relapsed or refractory Hodgkin′s lymphoma [J]. N Engl J Med，2015，372（4）：311-319.
[5] Powles T，Eder JP，Fine GD，et al. MPDL3280A（anti-PD-L1）treatment leads to clinical activity in metastatic bladder cancer [J]. Nature，2014，194（4）：558-562.
[6] Champiat S，Dercle L，Ammari S，et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 [J]. Clin Cancer Res，2017， 23（8）：1920-1928.
[7] Chubachi S，Yasuda H，Irie H，et al. A case of non-small cell lung cancer with possible “disease flare” on nivolumab treatment [J]. Case Rep Oncol Med，2016，2016：1075641.
[8] Ferrara R，Caramella C，Texier M，et al. Hyperprogressive disease（HPD）is frequent in non small cell lung cancer（NSCLC）patients（pts）treated with anti PD1/PD-L1 monoclonal antibodies（IO）[J]. Ann Oncol，2017，28（Suppl 5）：464-465.
[9] Sa?覾da-Bouzid E，Defaucheux C，Karabajakian A，et al. 1306PDHyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma [J]. Ann Oncol，2017，28（7）：1605-1611.
[10] Kato S，Goodman A，Walavalkar V，et al. Hyperprogressors after immunotherapy：analysis of genomic alterations associated with accelerated growth rate [J]. Clin Cancer Res，2017，23（15）：4242-4250.
[11] Singavi AK，Menon S，Kilari D，et al. 1140PDPredictive biomarkers for hyper-progression（HP）in response to immune checkpoint inhibitors（ICI）-analysis of somatic alterations（SAs）[J]. Ann Oncol，2017，28（Suppl 5）.
[12] Wolchok JD，Hoos A，O′Day S，et al. Guidelines for the evaluation of immune therapy activity in solid tumors：immune-related response criteria [J]. Clin Cancer Res，2009，15（23）：7412-7420.
[13] Tsien C，Galbán CJ，Chenevert TL，et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma [J]. J Clin Oncol，2010，28（13）：2293-2299.
[14] Wolchok JD，Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation [J]. Oncologist，2008，13（4）：2-9.
[15] Chiou VL，Burotto M. Pseudoprogression and immune-related response in solid tumors [J]. J Clin Oncol，2015，33（31）：3541-1543.
[16] Hodi FS，Hwu WJ，Kefford R，et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab [J]. J Clin Oncol，2016，34（13）：1510-1517.
[17] Kim HK，Heo MH，Lee HS，et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors [J]. Cancer Chemother Pharmacol，2017， 80（3）：591-598.
[18] Nishino M，Tirumani SH，Ramaiya NH，et al. Cancer immunotherapy and immune-related response assessment：the role of radiologists in the new arena of cancer treatment [J]. Eur J Radiol，2015，84（7）：1259-1268.
[19] Goronzy JJ，Weyand CM. Understanding immunosenescence to improve responses to vaccines [J]. Nat Immunol，2013，14（5）：428-436.
[20] Solana R，Tarazona R，Gayoso I，et al. Innate immunosenescence：effect of aging on cells and receptors of the innate immune system in humans [J]. Semin Immunol，2012， 24（5）：331-341.
[21] Brahmer J，Reckamp KL，Baas P，et al. Nivolumab versus docetaxel in advanced squamous-cell non small cell lung cancer [J]. N Engl J Med，2015，373（2）：123-135.
[22] Landre T，Taleb C，Nicolas P，et al. Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour? [J]. J Clin Oncol，2016， 34（15 Suppl）：3070.
[23] Hurez V，?魣 Padrón，Svatek RS，et al. Considerations for successful cancer immunotherapy in aged hosts [J]. Clin Exp Immunol，2016，187（1）：53-63.
[24] Padrón ?魣，Hurez V，Gupta HB，et al. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model [J]. Exp Gerontol，2018，105：146-154.
[25] Ogata T，Satake H，Ogata M，et al. Hyperprogressive disease in the irradiation field after a single dose of nivolumab for gastric cancer：a case report [J]. Case Rep Oncol，2018，11（1）：143-150.
[26] Peng W，Liu C，Xu C，et al. PD-1 blockade enhances T-cell migration to tumor through induction of IFN-γ inducible chemokines [J]. Cancer Res，2012，72（20）：5209-5218.
[27] Gainor JF，Shaw AT，Sequist LV，et al. EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer（NSCLC）：a retrospective analysis [J]. Clin Cancer Res，2016，22（18）：4585-4593.
[28] Akbay EA，Koyama S，Carretero J，et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors [J]. Cancer Discov，2013，3（12）：1355-1363.
[29] Garon EB，Rizvi NA，Hui R，et al. Pembrolizumab for the treatment of non small cell lung cancer [J]. N Engl J Med，2015，372（21）：2018-2028.
[30] Reck M，Rodríguez-Abreu D，Robinson AG，et al. Pembrolizumab versus chemotherapy for PD-L1 positive non small cell lung cancer [J]. N Engl J Med，2016，375（19）：1823-1833.
[31] Bylicki O，Paleiron N，Margery J，et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non small cell lung cancer [J]. Target Oncol，2017，12（5）：563-569.
[32] Lee CK，Man J，Lord S，et al. Checkpoint inhibitors in metastatic EGFR-mutated non small cell lung cancer—a meta analysis [J]. J Thorac Oncol，2017，12（2）：403-407.